

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Vital Innovations Holdings Limited

維太創科控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6133)

FURTHER INFORMATION ANNOUNCEMENT TO THE 2022 ANNUAL REPORT

Reference is made to the 2022 annual report (the “**2022 Annual Report**”) of Vital Innovations Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) published on 26 April 2023. The Company would like to provide the shareholders of the Company with further information in respect of the restricted share unit (“**RSU**”) scheme (the “**RSU Scheme**”) of the Company.

The participants of the RSU Scheme include (i) employee(s) (whether full time or part time), including any executive Director of the Company, its subsidiaries or any entity (the “**Invested Entity**”) in which the Group holds any equity interest; (ii) any non-executive director (including any independent non-executive director) of the Company, any of its subsidiaries or any Invested Entity; (iii) any supplier of goods or services to any member of the Group or any Invested Entity; (iv) any customer of the Group or any Invested Entity; (v) any person or entity that provides research, development or other technological support to the Group or any Invested Entity; (vi) any shareholder of any member of the Group or any Invested Entity or any holder of any securities issued by any member of the Group or any Invested Entity; (vii) any person or entity which has contributed to the Group or its business; and (viii) any other person selected by the Board at its sole discretion.

There is no maximum entitlement limit for each participant under the RSU Scheme. Unless otherwise specified by the grant letter, there is no amount payable on application or acceptance of the RSU and no purchase price for such RSU.

The total number of shares (the “**Share(s)**”) of the Company underlying the RSUs under the RSU Scheme shall not exceed 32,300,000 Shares (excluding Shares underlying RSUs that have lapsed or been cancelled in accordance with the RSU Scheme). As at the date of the 2022 Annual Report, all the Shares underlying the RSU Scheme have been granted and vested. As such, no Shares remained available for grant or will be issued under the RSU Scheme. The Company will comply with Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) if it adopts a new share scheme or arrangements within the meaning of Rule 17.01(1) of the Listing Rules.

By order of the Board
Vital Innovations Holdings Limited
Rong Xiuli
Chairperson

Hong Kong, 11 October 2023

As at the date of this announcement, the board of directors of the Company comprises Ms. Rong Xiuli, Mr. Rong Shengli, Mr. Yin Xuquan and Mr. Wong Ho Chun as executive directors, and Mr. Leung Man Fai, Mr. Wong Pong Chun James and Mr. Han Xiaojing as independent non-executive directors.